<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2381">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970333</url>
  </required_header>
  <id_info>
    <org_study_id>FEPPA 001</org_study_id>
    <nct_id>NCT00970333</nct_id>
  </id_info>
  <brief_title>Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions</brief_title>
  <official_title>Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ultimately a marker of microglial activation could be used for large-scale quantitative brain&#xD;
      imaging trials in Alzheimer Disease (AD), Parkinson Disease (PD) or Multiple Sclerosis (MS),&#xD;
      specifically to investigate the agent as an objective biomarker in treatments aimed at&#xD;
      reducing inflammatory changes in these conditions. The significance of this work lies in&#xD;
      applying state-of-art quantitative neuroimaging tools to develop a relevant biomarker in&#xD;
      individuals with neurodegenerative diseases with the intention of using this efficiently in&#xD;
      large clinical imaging trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The adaptation of imaging agents like [18F]-FEPPA as a biomarker of microglial activation in&#xD;
      neurodegenerative and neuroinflammatory diseases requires human validation studies. Expanding&#xD;
      upon our previous work with B-amyloid ligands (123I-IMPY, 123I MNI-187) for AD and dopamine&#xD;
      transporter ligands (123I B-CIT, Altropane) for PD, we desire to develop and characterize&#xD;
      [18F]-FEPPA as a potential marker for microglial activation in association with neuronal&#xD;
      damage that may be applicable to multiple neurodegenerative and inflammatory diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, [18F]-FEPPA.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Parkinson Disease</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>assess [18F]-FEPPA PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]-FEPPA</intervention_name>
    <description>Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not &gt;10% of 5 mCi limit) of [18F]-FEPPA followed by serial PET imaging</description>
    <arm_group_label>assess [18F]-FEPPA PET imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alzheimer's disease patients will be recruited for this study. The following criteria&#xD;
             will be met for inclusion of AD subjects in this study:&#xD;
&#xD;
               -  The participant is 50 years or older.&#xD;
&#xD;
               -  Written informed consent is obtained.&#xD;
&#xD;
               -  Participants have a clinical diagnosis of probable Alzheimer's disease based on&#xD;
                  National Institute of Neurological and Communicative Disorders and&#xD;
                  Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA)&#xD;
                  criteria.&#xD;
&#xD;
               -  Clinical Dementia Rating Scale score ≤ 2.&#xD;
&#xD;
               -  Modified Hachinski Ischemia Scale score of ≤ 4.&#xD;
&#xD;
               -  For females, non-child bearing potential or a negative urine or blood pregnancy&#xD;
                  test on day of [18F]-FEPPA injection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alzheimer's subjects will be excluded from participation for the following reasons:&#xD;
&#xD;
               -  The subject has a history of significant cerebrovascular disease.&#xD;
&#xD;
               -  The subject has a clinically significant abnormal laboratory value and/or&#xD;
                  clinically significant unstable medical or psychiatric illness&#xD;
&#xD;
               -  The subject has evidence of clinically significant gastrointestinal,&#xD;
                  cardiovascular, hepatic, renal, hematological, neoplastic, endocrine,&#xD;
                  neurological, immunodeficiency, pulmonary, or other disorder or disease.&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  The following criteria will be met for inclusion of PD subjects in this study:&#xD;
&#xD;
               -  The participant is 30 years or older.&#xD;
&#xD;
               -  Written informed consent is obtained.&#xD;
&#xD;
               -  Participants have a clinical diagnosis of Parkinson disease (at least two of the&#xD;
                  three cardinal symptoms: resting tremor, rigidity, bradykinesia).&#xD;
&#xD;
               -  Hoehn and Yahr ≤4.&#xD;
&#xD;
               -  For females, non-child bearing potential or a negative urine or blood pregnancy&#xD;
                  test on day of [18F]-FEPPA injection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parkinson's subjects will be excluded from participation for the following reasons:&#xD;
&#xD;
               -  The subject has a clinically significant abnormal laboratory value and/or&#xD;
                  clinically significant unstable medical or psychiatric illness&#xD;
&#xD;
               -  The subject has evidence of clinically significant gastrointestinal,&#xD;
                  cardiovascular, hepatic, renal, hematological, neoplastic, endocrine,&#xD;
                  neurological, immunodeficiency, pulmonary, or other disorder or disease.&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple Sclerosis Subject Selection. Subjects who have a clinical diagnosis of&#xD;
             Multiple Sclerosis (MS) will be recruited for this study. The following criteria will&#xD;
             be met for inclusion of MS subjects in this study:&#xD;
&#xD;
               -  The participant is 18 years or older.&#xD;
&#xD;
               -  Written informed consent is obtained.&#xD;
&#xD;
               -  Participants have a clinical diagnosis of Multiple Sclerosis (per the 2005&#xD;
                  Revised McDonald Criteria; Polman, et al., 2005).&#xD;
&#xD;
               -  Kurtzke Expanded Disability Status Scale (EDSS) ≤ 7.5.&#xD;
&#xD;
               -  For females, non-child bearing potential or a negative urine or blood pregnancy&#xD;
                  test on day of [18F]-FEPPA injection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MS subjects will be excluded from participation for the following reasons:&#xD;
&#xD;
               -  The subject has a clinically significant abnormal laboratory value and/or&#xD;
                  clinically significant unstable medical or psychiatric illness&#xD;
&#xD;
               -  The subject has evidence of clinically significant gastrointestinal,&#xD;
                  cardiovascular, hepatic, renal, hematological, neoplastic, endocrine,&#xD;
                  neurological, immunodeficiency, pulmonary, or other disorder or disease.&#xD;
&#xD;
               -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instiute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>February 7, 2012</last_update_submitted>
  <last_update_submitted_qc>February 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Neurodegenerative Disorders</investigator_affiliation>
    <investigator_full_name>Danna Jennings, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer disease</keyword>
  <keyword>Parkinson disease</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

